Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MiNK Therapeutics, Inc. (INKT : NSDQ)

• Company Description    MiNK Therapeutics Inc. is a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics Inc. is headquartered in New York. Number of Employees: 15

• Price / Volume Information    Yesterday's Closing Price: $10.87 Daily Weekly Monthly 20 Day Moving Average: 28,693 shares Shares Outstanding: 4.98 (millions) Market Capitalization: $54.15 (millions) Beta: 0.47 52 Week High: $52.50 52 Week Low: $6.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.30% -3.64% 12 Week -1.45% -8.90% Year To Date -2.51% -9.79%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 149 Fifth Avenue Suite 500 - New York,NY 10010 USA ph: 212-994-8250 fax: - investor@minktherapeutics.com http://www.minktherapeutics.com

• General Corporate Information    Officers Jennifer S. Buell - President; Chief Executive Officer and Director Garo H. Armen - Chairman Melissa Orilall - Principal Financial Officer Austin Charette - Principal Accounting Officer Peter Behner - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 603693201 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 4.98 Most Recent Split Date: 1.00 (0.10:1) Beta: 0.47 Market Capitalization: $54.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.60 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.74 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 18.57% vs. Previous Quarter: -1.79% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - - ROA 03/31/26 - -118.57 12/31/25 - -139.00 09/30/25 - -180.14 Current Ratio 03/31/26 - 1.38 12/31/25 - 1.06 09/30/25 - 1.08 Quick Ratio 03/31/26 - - 12/31/25 - 1.06 09/30/25 - 1.08 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - -2.55 12/31/25 - -3.03 09/30/25 - -2.94 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©